Literature DB >> 9709784

Perceptions and preferences of autologous blood donors.

S J Lee1, B Liljas, W H Churchill, M A Popovsky, C P Stowell, M E Cannon, M Johannesson.   

Abstract

BACKGROUND: The public's perception of autologous blood donation and transfusion as a worthwhile alternative to allogeneic blood transfusion increased dramatically with discovery of the human immunodeficiency virus. However, new concerns are being raised about the health outcomes and cost-effectiveness of the procedure. As more restrictive guidelines for autologous blood donation evolve, opposition from patients concerned about exposure to allogeneic blood may arise. Physicians' ability to reassure patients and garner their support for more restrictive policies requires an understanding of patients' concerns. The motivations, perceptions, and preferences of patients currently participating in autologous blood donation programs were investigated in this study. STUDY DESIGN AND METHODS: Results from two questionnaire studies of 647 autologous blood donors are presented. The questionnaires assessed demographics, risk perceptions, preferences, willingness to pay, and reactions to different interventions designed to decrease patient preference for autologous blood donation.
RESULTS: Patients expressed a strong preference for the availability of autologous blood and indicated that they would be willing to pay substantial amounts of money even if the procedure were not covered by insurance. Despite education about the low risks of complications from allogeneic transfusions, an aversion to allogeneic transfusion and a willingness to pay for autologous blood donation persisted. Patients were not reassured by information on better infectious disease testing or physician recommendation against autologous blood donation.
CONCLUSION: Patients currently participating in autologous blood donor programs strongly prefer continued access to this procedure, primarily because they remain concerned about the complications of allogeneic transfusions. They may not be significantly reassured despite increasingly rigorous and costly improvements in donor and component screening.

Entities:  

Mesh:

Year:  1998        PMID: 9709784     DOI: 10.1046/j.1537-2995.1998.38898375515.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Minorities are less likely to receive autologous blood transfusion for major elective orthopaedic surgery.

Authors:  Mariano E Menendez; David Ring
Journal:  Clin Orthop Relat Res       Date:  2014-07-16       Impact factor: 4.176

2.  [Preoperative autologous blood donation in cardiac surgery. Reduction of allogeneic blood requirements].

Authors:  W Dietrich; R Busley; M Kriner
Journal:  Anaesthesist       Date:  2006-07       Impact factor: 1.041

3.  Autologous versus allogeneic transfusion: patients' perceptions and experiences.

Authors:  I D Graham; D Fergusson; H Dokainish; J Biggs; L McAuley; A Laupacis
Journal:  CMAJ       Date:  1999-04-06       Impact factor: 8.262

4.  Transfusion practices for elective orthopedic surgery.

Authors:  Brian G Feagan; Cindy J Wong; William C Johnston; Ramiro Arellano; Nigel Colterjohn; Keyvan Karkouti; Kim Turner
Journal:  CMAJ       Date:  2002-02-05       Impact factor: 8.262

5.  Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods.

Authors:  Diego F Ossa; Andrew Briggs; Emma McIntosh; Warren Cowell; Tim Littlewood; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  A survey of blood conservation methods in clinical practice in some urban south-eastern government hospitals in Nigeria.

Authors:  A O Amucheazi; V O Ajuzeiogu; H A Ezike; M C Odiakosa; O M Nwoke; E Onyia
Journal:  Asian J Transfus Sci       Date:  2011-01

Review 7.  Preoperative recombinant human erythropoietin in anemic surgical patients.

Authors:  Terri G Monk
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.